NCT02149095View on ClinicalTrials.gov

Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2014

Primary Completion Date

November 30, 2014

Conditions
PAH
Interventions
DRUG

TransCon PEG treprostinil

Trial Locations (1)

78744

PPD Development, Austin

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY

NCT02149095 - Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter